Verastem, Inc. (VSTM) News
Follow Verastem, Inc. (VSTM) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Verastem Oncology Posts 2-Year Follow-Up Data From RAMP 201
Verastem Oncology reported two-year median follow-up results from Phase 2 RAMP 201 in recurrent LGSOC, showing durable efficacy and no new safety signals, including an increase in median DoR for KRAS wild-type patients f
NEWS | Sep 28, 2026, 08:10 PM UTC
L
Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that Gynecologic Oncology, the official journal of the
NEWS | Sep 28, 2026, 08:10 PM UTC
H
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that an abstract about molecular profiling and tumor b
NEWS | Sep 24, 2026, 12:30 PM UTC
L
VSTM: Advancing RAS/MAPK therapies with pivotal trials and new data to expand cancer treatment options
The session highlighted progress in commercial and clinical programs for RAS/MAPK-driven therapies, including a strong launch for the CO-PACK in ovarian cancer and advancing VS-7375 in multiple tumor types. Key upcoming
NEWS | Sep 14, 2026, 07:29 PM UTC
L
VSTM: Advancing selective KRAS therapies with robust clinical progress and upcoming pivotal data
The session highlighted strong commercial and clinical progress for a KRAS-mutated ovarian cancer therapy and the advancement of a selective KRAS G12D inhibitor across multiple tumor types. Upcoming data readouts and new
NEWS | Sep 14, 2026, 07:01 PM UTC
L
VSTM: Pivotal G12D inhibitor data and commercial momentum drive expansion and strategic partnerships
Key updates include strong progress in the G12D inhibitor program with pivotal data expected in October, robust commercial growth for avutometinib/defactinib, and strategic plans for phase III trials and partnerships. Th
EQUITY | Sep 10, 2026, 02:00 PM UTC
L
VSTM: Major data update for G12D inhibitor set for October, with phase III trials and partnerships ahead
Significant clinical progress was highlighted for the G12D inhibitor, with major data updates expected in October and phase III trials planned for next year. The drug is positioned as best-in-class, with strong efficacy,
EQUITY | Sep 10, 2026, 01:34 PM UTC
L
Verastem Oncology to host Oct. 14 investor event for VS-7375 data
Verastem Oncology said it will host an investor event on Wednesday, October 14, at 8:00 am ET to present initial efficacy and updated safety and tolerability for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor.
EQUITY | Sep 08, 2026, 11:30 AM UTC
L
Verastem Oncology to participate in Sept. 8 investor conference
Verastem Oncology said its management team is scheduled to participate at the Wells Fargo 21st Annual Healthcare Conference on Sept. 8 in Boston.
EQUITY | Sep 02, 2026, 11:30 AM UTC
L
VSTM Verastem Oncology doses first patient in target-d 203 phase 2 registration-directed trial of vs-7375 oral kras g12d (on/off) inhibitor
VSTM Verastem Oncology doses first patient in target-d 203 phase 2 registration-directed trial of vs-7375 oral kras g12d (on/off) inhibitor for kras g12d-mutated metastatic colorectal cancer
EQUITY | Jul 28, 2026, 08:01 PM UTC
H
Verastem price target lowered to $14 from $15 at RBC Capital
RBC Capital lowered the firm's price target on Verastem to $14 from $15 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has picked up
EQUITY | Jul 07, 2026, 11:32 AM UTC
H
VSTM: Reports Encouraging VS-7375 Data
Verastem Oncology reports encouraging clinical activity and favorable safety profile for VS-7375 in Phase 1/2 clinical study
EQUITY | Jun 23, 2026, 08:05 PM UTC
H
VSTM Shows Promise
VSTM's VS-7375 demonstrates clinical activity with favorable safety in Phase 1/2 trial for KRAS G12D-mutated solid tumors
EQUITY | Jun 23, 2026, 08:01 PM UTC